In general, I am a believer in management or surveillance biopsies. However, I also think there should be low threshold to forego the biopsy should it put the patient at increased risk, such as anticoagulation or intraperitoneal kidney. The other consideration is what is your plan for treating, or n...

At our center, we do 6-month surveillance biopsies for all patients as standard of care. Our subclinical rejection rate is under 10%.I think it is still a matter of controversy if surveillance biopsies help improve outcomes. Each center has to decide based on their patient demographics/outcomes and ...

Agree with both Drs. @Ong and @Adey on their assessment of the utility of using surveillance biopsies. The reality is that many transplant centers have outsourced their renal allograft biopsies to radiology/IR, and thus may not have the same degree of control over how and when biopsies are performed...